RZLT
- Rezolute, Inc.
()
Overview
Company Summary
Rezolute, Inc. is a biopharmaceutical company that specializes in the development of innovative therapies for people with metabolic and rare diseases. The company focuses on addressing unmet needs in the field of endocrinology, which is the study of hormones and the disorders related to them.
Rezolute's primary goal is to improve the lives of patients by developing novel and effective treatments. They achieve this through their expertise in peptide and protein engineering, as well as their deep understanding of endocrine disorders.
One of their flagship products is RZ358, which is being developed as a potential treatment for congenital hyperinsulinism (CHI), a rare metabolic disorder characterized by abnormal insulin levels. CHI can cause dangerous hypoglycemia, seizure, and even death in infants and children. RZ358 aims to provide a targeted therapy to manage this condition effectively.
Additionally, Rezolute is also advancing other pipeline candidates, including AB101, being developed for diabetic macular edema (DME), and RZ402, targeting mitochondrial diseases. These candidates demonstrate their commitment to addressing various metabolic and rare diseases where treatment options are limited.
Rezolute employs a research-driven and patient-centric approach, collaborating with leading clinicians, scientists, and research institutions to advance their product candidates. By focusing on innovative science and advanced technologies, they strive to bring transformative medical treatments to patients in need.
In summary, Rezolute, Inc. is a biopharmaceutical company dedicated to developing therapies for metabolic and rare diseases by leveraging cutting-edge technologies and scientific expertise in the field of endocrinology.